Novo Nordisk’s Oral Wegovy Pill Defies Expectations as Data Blitz Reshapes Obesity Market Battle
Novo Nordisk’s oral Wegovy pill nearly doubled sales forecasts, with Istanbul congress data showing early responders achieve 21.6%…
Novo Nordisk’s Oral Wegovy Defies Gravity as FDA Poised to Curb Compounders
Novo Nordisk’s new Wegovy pill generates 2.26B DKK in Q1, double forecasts; revenue jumps 32% to 96.82B DKK.…
Novo Nordisk’s Share Buyback Defies a Challenging Outlook
Novo Nordisk spends billions on share buybacks despite forecasting a 5-13% sales and profit decline for 2026. Stock…
Andalucía defies global turmoil and sets record goals at ITB Berlin
Friday, 6 March 2026, 11:44 | Updated 12:41h. The 2026 ITB Berlin travel trade show opened with a…